Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers to phenotype type 2 diabetic patients and personalize treatment
2024-516542-19-00Phase 4Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide arm with Dapagliflozin arm (2 arms). Planned start Oct 2024; status: authorised.
02
Drugs
semaglutidedapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-516542-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516542-19-00.